Vimarsana
Biggest News Aggregation in the World

Page 36 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Risk Evaluation Today - Breaking & Trending Today

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023 - Vimarsana News

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Published: September 11, 2023

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were...

Source: prnewswire.com
Related Topics:
United StatesUniversity Of South CarolinaSouth CarolinaRichardk BoganAndrean FlynnKelvin TanKristin BhavnaniPsych CongressWorld Idiopathic Hypersomnia Total Health ModelUnmet Public Health ProblemIndian Journal Of Medical ResearchAmerican Psychiatric AssociationNational Health ServiceNational Institute Of Neurological DisordersAmerican Academy Of Sleep MedicineHead Of Global Corporate CommunicationsInternational Classification Of Sleep DisordersGlobal Psychiatry Behavioral Health Learning NetworkDrug AdministrationUniversity Of South Carolina School MedicineOffice Of Orphan Product DevelopmentNational Academies PressJazz PharmaceuticalsJazz Pharmaceuticals IncDrug Enforcement Agency
Spravato Safety Holds Up Long-Term for Treatment-Resistant Depression - Vimarsana News

Spravato Safety Holds Up Long-Term for Treatment-Resistant Depression

Published: September 11, 2023

Most adverse events dissipated after second or third treatment with intranasal esketamine

Source: medpagetoday.com
Related Topics:
New YorkUnited StatesMichael DepeauReina BenabouUnited States Psych CongressPsych CongressPysch CongressJanssen NeuroscienceNew York CityMontgomery Asberg Depression Rating ScaleRisk EvaluationMitigation StrategyMedpage Today
BÖRSE ONLINE – Seit 1987, Deutschlands erstes Börsenmagazin - Vimarsana News

BÖRSE ONLINE – Seit 1987, Deutschlands erstes Börsenmagazin

Published: September 6, 2023

Seit 1987 hilft BÖRSE ONLINE Anlegern Woche für Woche bei ihren Investmententscheidungen.

Source: boerse-online.de
Related Topics:
Switzerland GeneralUnited StatesMarkus SchlaichJean Paul ClozelJanssen Pharmaceutical Companies Of JohnsonJanssen Biotech IncIdorsia LtdJanssen Pharmaceutical CompaniesPaul ClozelChief Financial OfficerPrescription Drug User Fee ActRisk EvaluationMitigation StrategyAfrican AmericanNorth America
GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan - Vimarsana News

GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan

Published: September 6, 2023

^Ad hoc announcement pursuant to Art. 53 LR * Aprocitentan, Idorsia's oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension. * Idorsia will pay Janssen a conditional consideration up to a total cap of...

Source: boersennews.de
Related Topics:
Switzerland GeneralUnited StatesJean Paul ClozelMarkus SchlaichJanssen Biotech IncJanssen Pharmaceutical CompaniesIdorsia LtdPaul ClozelChief Financial OfficerPrescription Drug User Fee ActRisk EvaluationMitigation StrategyNorth AmericaDorsia S
Börse Express - GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan - Vimarsana News

Börse Express - GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan

Published: September 6, 2023

^Ad hoc announcement pursuant to Art. 53 LR

Source: boerse-express.com
Related Topics:
United StatesSwitzerland GeneralWirtschaftsnachrichten GmbJean Paul ClozelMarkus SchlaichJanssen Biotech IncJanssen Pharmaceutical CompaniesIdorsia LtdPaul ClozelChief Financial OfficerPrescription Drug User Fee ActRisk EvaluationMitigation StrategyNorth AmericaAlle RechteOhnson Amp JohnsonPne AgDow JonesOw Jones DbDirect Market